McKessonNYSE: MCK

MCK is still growing due to strong performance in different areas and an improved forecast for the fiscal year 2025.

McKesson's cell and gene therapies business is set to provide patients with better treatment choices for sickle cell disease (SCD) thanks to the availability of the FDA-approved drug. This development is anticipated to enhance the care options for those affected by the condition.

McKesson (MCK) has received an upgrade to a Zacks Rank #2 (Buy), indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.

McKesson (MCK) has strong growth characteristics that may enable it to perform better than the market.

No matter if you focus on value, growth, or momentum investing, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.

I maintain a 'Strong Buy' recommendation for McKesson, supported by the growth of GLP-1 drugs and a strong oncology network, with a target price of $696 per share. The company's purchase of a 70% stake in Florida Cancer Specialists strengthens its oncology network, now reaching 3,300 providers in 31 states. Additionally, McKesson reported impressive Q2 results, showing a 21% increase in revenue and raising its EPS forecast to between $32.40 and $33.00, thanks to specialty distribution and retail national account clients.

McKesson's results for the second quarter of fiscal 2025 show an increase in the U.S. Pharmaceutical division. On the other hand, the Medical Surgical Solutions segment is facing challenges because of reduced sales related to COVID.

While the revenue and earnings per share (EPS) for McKesson (MCK) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

On Wednesday, McKesson Corp, a drug distributor, increased its yearly profit prediction due to higher sales in its U.S. pharmaceuticals division, which is benefiting from strong demand for specialty and branded medications.